Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 1637: The MEK/Erk pathway is required for PC3 cell survival following FdUMP[10] treatment

Evan Gomes, Jamie Jennings-Gee and William H. Gmeiner
Evan Gomes
1Wake Forest Univ. School of Medicine, Winston-Salem, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie Jennings-Gee
1Wake Forest Univ. School of Medicine, Winston-Salem, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William H. Gmeiner
1Wake Forest Univ. School of Medicine, Winston-Salem, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-1637 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

We have demonstrated that the novel polymeric fluoropyrimidine (FP) antitumor agent FdUMP[10] is efficacious towards prostate tumor (PC3) xenografts at well-tolerated doses while 5-fluorouracil (5FU) is not efficacious. FdUMP[10] treatment of PC3 cells results in complete inhibition of thymidylate synthase and S-phase arrest with generation of extensive DNA double-strand breaks as detected from γH2AX phosphorylation. S-phase arrest was confirmed by Western blots evaluating cyclin expression. In addition, we show that although cell-cycle arrested, FdUMP[10]-treated PC3 cells are not quiescent as indicated by extensive levels of DNA synthesis. The elevated DNA synthesis levels are likely indicative of futile repair. Although approximately 90% of cells are non-viable as assessed by a clonogenic assay, only about 30% of cells undergo apoptosis as assessed by Annexin V+ cells. The observation that FdUMP[10] treatment resulted in potent anti-tumor activity with minimal induction of apoptotic events lead us to assess to what extent activation of cell survival pathways inhibited cell death. The phosphoinositide 3-kinase PI3K/Akt and the mitogen-activated protein kinase kinase/extracellular signal-regulated protein kinases (MEK/ERK1/2) signal transduction pathways play critical roles in mammalian cell survival and have been shown to be activated in various cancers. Previous studies have shown that inhibition of PI3K/Akt or MEK/ERK1/2 can each enhance the effectiveness of cytotoxic chemotherapy. Our results show that FdUMP[10] treatment reduced phosphorylated Akt levels suggesting FdUMP[10] treatment inactivates the PI3K/Akt pro-survival pathway. However, inhibition of PI3K/Akt with LY294002 alone promoted a significant loss in the clonogenic capacity of PC3 cells independent of FdUMP[10] treatment while co-treatment did not provide an enhanced therapeutic effect. In contrast to these findings, inhibition of the MEK/ERK1/2 pathway with U0126 showed a significant decrease in viability only in combination with FdUMP[10] treatment. Here, we demonstrate that the potent effects of FdUMP[10]-induced cytotoxicity towards prostate cancer cells may be exacerbated by impairment of the MEK/ERK1/2 but not the PI3K/Akt cell survival pathway. Altogether, our studies suggest advanced prostate cancer may be amenable to treatment with FdUMP[10] in combination with inhibitors of MAPK signaling.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1637.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 1637: The MEK/Erk pathway is required for PC3 cell survival following FdUMP[10] treatment
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 1637: The MEK/Erk pathway is required for PC3 cell survival following FdUMP[10] treatment
Evan Gomes, Jamie Jennings-Gee and William H. Gmeiner
Cancer Res April 15 2010 (70) (8 Supplement) 1637; DOI: 10.1158/1538-7445.AM10-1637

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 1637: The MEK/Erk pathway is required for PC3 cell survival following FdUMP[10] treatment
Evan Gomes, Jamie Jennings-Gee and William H. Gmeiner
Cancer Res April 15 2010 (70) (8 Supplement) 1637; DOI: 10.1158/1538-7445.AM10-1637
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Novel Mechanisms of Drug Action and Signaling Pathways

  • Abstract 1644: Sunitinib primarily acts on tumor endothelium but not tumor cells to inhibit renal cell carcinoma tumor growth
  • Abstract 1656: Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells
  • Abstract 1660: The antitumor action of ASA404 (vadimezan; DMXAA); potential involvement of vascular endothelial growth factor (VEGF)
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement